Novo Nordisk's stock rose last week after the company reported a strong market launch for its Wegovy weight-loss pill, with prescriptions for its semaglutide tablet surpassing 3 million in just over five months. This early data signals a positive trend: the drug has not only attracted injectable users switching to the tablet version, but over 80% of users are first-time GLP-1 class drug users. This news is a bright spot for the company, which has been working to reverse its fortunes after losing significant market share in weight-loss drugs to Eli Lilly.

To regain growth momentum, Novo Nordisk has undergone significant restructuring. Last summer, the company appointed Maziar Mike Doustdar as its new CEO and implemented a board restructuring, a round of layoffs, and pipeline adjustments. These measures aim to optimize strategic positioning and address competitive market pressures.

Novo Nordisk's executive changes are not an isolated case, as Genentech and Allogene have also recently seen leadership adjustments. Below are the details of these changes.

Novo Nordisk Loses Another Key Executive

The latest executive to leave Novo Nordisk is John McDonald, who served as the company's Corporate Vice President and Head of Global Business Development and M&A. He joined the company in October 2018 and, after nearly eight years, has moved to venture capital firm Forbion. According to his LinkedIn profile, during his tenure he led several major Novo Nordisk acquisitions, including the 2020 acquisition of Corvidia Therapeutics (with a deal value of up to $2.1 billion) and the 2021 acquisition of Dicerna for $3.3 billion.

With extensive pharmaceutical industry experience gained at Novo Nordisk, Biogen, Millennium Pharmaceuticals, and Genzyme, McDonald will bolster Forbion's biotechnology investment operations.

Genentech Conducts Multi-Department Layoffs

Three Genentech executives were affected by the restructuring of the Research and Early Development department in June, as initially reported by Endpoints News. Dr. Vishva Dixit, who had been with the company for nearly 30 years, left his role as Vice President and Senior Fellow of Physiological Chemistry and Research Biology; Todd McDevitt, Vice President and Head of the Cell Therapy department; and Dr. Man-Wah Tan, Vice President and Senior Fellow of Research Biology and Infectious Diseases, were also among those let go. Endpoints reported that these changes stem from the company's decision to shut down its physiological chemistry and infectious disease teams.

In 2025, Genentech also conducted three rounds of layoffs in October, July, and June, affecting nearly 350 employees in the Bay Area and South San Francisco. Genentech is not the only company adjusting pipeline priorities this year, as more pharmaceutical companies shift toward leaner but more strategically focused pipelines.

Although layoffs are expected to slow in 2026 compared to 2025, job cuts within the industry will continue.

Allogene Welcomes New CEO

Allogene Therapeutics, which specializes in off-the-shelf CAR-T therapies, announced that Chief Medical Officer Dr. Zachary Roberts will assume the role of CEO on July 1. His appointment comes as current CEO Dr. David Chang prepares to step down, which the company describes as a "planned succession." Dr. Chang will remain on the board.

In a written statement, Dr. Chang said: "It has been my privilege to serve as CEO of Allogene for the past eight years. As the company enters its next phase, this is the right time for a leadership transition, and Zach is the right person to lead Allogene forward. He is a highly respected physician-scientist and a dynamic leader with a clear vision for how emerging technologies can continue to expand the potential of allogeneic CAR-T."

This change comes as Allogene advances its cemacabtagene ansegedleucel therapy as a first-line treatment for large B-cell lymphoma. The company previously reported positive interim futility analysis results from its Phase 2 study, which drove the stock up 50%. The study evaluated the therapy's improvement in minimal residual disease clearance rates compared to the observation group, showing an absolute difference of 41.6% in MRD clearance, with patients tolerating it well. However, whether these results will continue to demonstrate the therapy's potential as the trial progresses remains to be seen.

Meanwhile, Allogene is also awaiting data from the Phase 1 trial of its autoimmune disease therapy, ALLO-329.